期刊文献+

分化型甲状腺癌肺转移危险因素分析 被引量:8

下载PDF
导出
摘要 目的探讨分化型甲状腺癌(DTC)肺转移的危险因素。方法回顾性分析接受治疗的222例DTC患者的临床资料,其中肺转移37例(16.7%)。按纳入标准共199例入选,通过131I全身扫描、甲状腺球蛋白>2μg/L、PET/CT、胸部X线、CT或肺结节组织病理确诊肺转移。纳入所有患者性别、年龄、原发灶病理资料(类型、病灶最大径、单或多灶、甲状腺包膜侵犯、甲状腺外组织侵犯、癌栓、甲状腺基础疾病、颈部淋巴结转移个数、纵隔淋巴结转移),筛选出DTC肺转移的危险因素。结果 199例患者中,单因素分析显示性别、原发肿瘤类型、最大径、多灶性、甲状腺包膜侵犯、甲状腺外组织侵犯、纵隔淋巴结转移和颈部淋巴结转移个数与肺转移有关(2值分别为4.106、5.045、31.452、16.516、18.503、16.577、21.997、25.728,均P<0.05),而年龄、基础原发病、癌栓与肺转移无关(2值分别为0.436、4.831、0.105,均P>0.05)。多因素logistic回归分析得到肺转移与原发灶最大径(P=0.011,OR=3.421)、多灶(P=0.016,OR=7.894)、包膜侵犯(P=0.018,OR=4.940)、颈部淋巴结转移个数(P=0.034,OR=2.393)及纵隔淋巴结转移(P=0.021,OR=5.121)相关。结论 DTC患者病灶最大径大于2.0 cm、多灶、包膜侵犯、纵隔淋巴结转移及颈部淋巴结>5个发生肺转移风险增加。
出处 《广东医学》 CAS 北大核心 2015年第9期1405-1407,共3页 Guangdong Medical Journal
  • 相关文献

参考文献15

  • 1LEE Y S,LIM Y S,LEE J C,et al.Clinical implications of bilateral lateral cervical lymph node metastasis in papillary thyroid cancer:a risk factor for lung metastasis[J].Ann Surg Oncol,2011,18(12):3486-3492. 被引量:1
  • 2KALENDER E,ZEKI CELEN Y,ELBOGA U,et al.Lung me-tastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy[J].Rev Esp Med Nucl Imagen Mol,2012,31(6):328-331. 被引量:1
  • 3National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:thyroid carcinoma[R].Version 2.2014. 被引量:1
  • 4DELELLIS R A,LLOYD R V,HEITZ P U,et al.World Health Organization classification of tumours:pathology and genetics of tumours of endocrine organs[R].Lyon:IARC Press,2004. 被引量:1
  • 5MASSIN J P,SAVOIE J C,GARNIER H,et al.Pulmonary me-tastases in differentiated thyroid carcinoma.Study of 58 cases with implications for the primary tumor treatment[J].Cancer,1984,53(4):982-992. 被引量:1
  • 6余永利,罗全勇,陈立波,罗琼,丁颖,陆汉魁,朱瑞森,马寄晓.分化型甲状腺癌术后~131Ⅰ治疗生存率分析[J].中华核医学杂志,2006,26(5):261-263. 被引量:21
  • 7MACHENS A,DRALLE H.Prediction of mediastinal lymph node metastasis in papillary thyroid cancer[J].Ann Surg Oncol,2009,16(1):171-176. 被引量:1
  • 8MACHENS A,DRALLE H.Correlation between the number of lymph node metastases and lung metastasis in papillary thyroid cancer[J].J Clin Endocrinol Metab,2012,97(12);4375-4382. 被引量:1
  • 9CHOPRA S,GARG A,BALLAL S,et al.Lung metastases from differentiated thyroid carcinoma:prognostic factors related to remission and disease free survival[J].Clin Endocrinol(Oxf),2015,82(3):445-452. 被引量:1
  • 10NIXON I J,WHITCHER M,PALMER F L.The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland[J].Thyroid,2012,22(9):884-889. 被引量:1

二级参考文献8

  • 1Kouvaraki MA,Shapiro SE,Lee JE,et al.Surgical management of thyroid carcinoma.J Natl Compr Canc Netw,2005,3:458-466. 被引量:1
  • 2Mazzaferri EL,Kloos RT.Current approaches to primary therapy for papillary and follicular thyroid cancer.J Clin Endocrinol Metab,2001,86:1447-1463. 被引量:1
  • 3Hay ID,Thompson GB,Grant CS,et al.Papillary thyroid carcinoma managed at the Mayo Clinic during six decades(1940-1999):temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.World J Surg,2002,26:879-885. 被引量:1
  • 4Derey TW,Paul GG.Role of 131I in the treatment of well differentiated thyroid cancer.J Gurg Oncol,2005,89:114-121. 被引量:1
  • 5Parthasarathy KL,Crawford ES.Treatment of thyroid carcinoma:emphasis on high-dose 131I outpatient therapy.J Nucl Med Technol,2002,30:165-171. 被引量:1
  • 6Yamashita HM.Locally recurrent thyroid carcinoma.In:Noguchi OHCaS,eds.Thyroid cancer:diagnosis and treatment.St.Louis:Quality Medical Publishing,Inc,2000.312-321 被引量:1
  • 7Sophie L,Carole R,Eric B,et al.Prognosis factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.J Clin Endocrinol Metab,2005,90:1210-1215. 被引量:1
  • 8Liu JD,Hsieh SH,Chang HY,et al.Outcome after treatment for papillary thyroid cancer.Head Neck,2001,23:140-146. 被引量:1

共引文献20

同被引文献63

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部